ERBB2 and gastric cancer: In addition, KEYNOTE-811study [11] showed that first-line pembrolizumab combined with trastuzumab and chemotherapy dramatically reduces tumour size, induces complete responses and significantly improves ORR in some human epidermal growth factor receptor-2(Her2)-positive advanced gastric cancer patients.